SanBio's after-hours PTS price is ¥947.1, down ¥3.9 from the previous closing price. The company announced its interim results on 14 September. For the interim period of the fiscal year ending January 2027, revenue was zero, while operating loss was ¥1.9 billion and net loss was ¥1.8 billion, with foreign exchange gains narrowing ordinary loss. The impact of the start of AQUGO sales will be closely watched.
The after-hours PTS trading price on 25 September was ¥947.1, down ¥3.9 from the Tokyo Stock Exchange closing price. After-hours trading is conducted through J-Market operated by Japannext Securities, with movements in trading prices and trading volume displayed as real-time updates.
In the interim results for the fiscal year ending January 2027, revenue remained at zero, while operating loss was ¥1.9 billion and net loss was ¥18. Compared with the same period of the previous year, ordinary loss narrowed to ¥1.7 billion due to the impact of foreign exchange gains.
The start of AQUGO sales in May 2026 has been reported and is attracting attention as a measure toward future monetisation. Long-term growth opportunities are anticipated, including the development of manufacturing and supply systems and preparations for a Phase 3 trial in the United States.
A summary of the earnings report and key performance checkpoints are also provided, with future development progress and market expansion trends identified as areas of investor focus.